Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of EGFR/HER3 Dual Payload Bispecific ADC JSKN021

JSKN021 is the company’s sixth ADC candidate entering clinical development, as well as its first dual payload ADC to advance into clinical trials
2026 ASCO | Alphamab Oncology Presented Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer

JSKN016 demonstrated very promising efficacy and superior safety profile in late line HER2-negative BC patients
2026 ASCO | Alphamab Oncology Announces Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Presented at LBA Oral Presentation Session

This study is the first Phase III clinical trial worldwide to directly demonstrate that a bispecific antibody has superior efficacy to the combination of two monospecific antibodies targeting the same tumor antigen, highlighting the leadership and superiority of Alphamab's platform technology

Vision, Mission and Core Values

Our Mission : To enable long-term, high-quality survival for cancer patients

Our Vision : To build a biopharmaceutical company with sustained innovation and global competitiveness

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

Learn More

Glycan-specific Conjugation Platform
Bispecific Antibody Platform
Subcutaneous Formulation Platform

Revolutionary Technology in Cancer Therapeutics

This platform leverages antibody Fc glycan-specific conjugation technology, utilizing an innovative one-enzyme two-step method that simplifies processes and reduces costs. It enables the development of ADCs with highly uniform DAR, demonstrating superior serum stability, enhanced bystander effects, and a broader therapeutic window, while minimizing toxicity risks. The platform has been validated for industrial-scale production and is currently expanding to develop dual-payload ADCs with customizable DAR values. Additionally, it can be integrated with other conjugation technologies, such as thiol-based conjugation and microbial transglutaminase (mTG), to generate a diverse array of next-generation ADCs.

Learn More

Globally Leading Bispecific Antibody Development Platform

This platform integrates two core technologies: the Fc-based CRIB (Charge Repulsion Induced Bispecific) heterodimer platform and the single-domain antibody assembly platform. The CRIB technology overcomes critical CMC (Chemistry, Manufacturing, and Control) challenges in asymmetric bispecific antibody production, enabling stable manufacturing of high-purity bispecific antibodies. The single-domain antibody assembly technology allows flexible construction of quadrivalent symmetric bispecific antibodies, which enhance tumor targeting precision through dual-target synergy while minimizing off-target risks. The platform’s advantages have been validated across multiple product candidates.

Learn More

Innovation in Drug Administration Technology

Subcutaneous high concentration formulation platform has successfully overcome technical barriers in developing high-concentration (≥150 mg/mL) liquid formulations for antibody drugs, enabling long-term stable storage (24-month stability under 2-8℃conditions). It has completed the commercial formulation development for products such as KN035 (PD-L1 single-domain antibody), with patient compliance surveys showing a satisfaction rate of 92%. For ADCs, the platform offers subcutaneous formulations that reduce infusion reactions (incidence lowered to <5%) and hematologic toxicity associated with intravenous administration.

Learn More